Antiviral Drug Discovery & Development Conference to Feature Big Pharma Advances in Respiratory/Influenza, HIV, & HBV/HCV in March, in Princeton, NJ
20.12.1999, 10:45
PRINCETON, N.J., USA (PROTEXT) - A major new, internationalconference presenting the newest advances by the pharmaceuticalindustry in developing novel drugs to fight viral diseases,including respiratory/influenza, HIV, and hepatitis B & C, willtake place on March 15-16, 2000 at the Hyatt Regency Hotel inPrinceton, NJ, announces Strategic Research Institute. The conference will feature new flu compounds targetingneuraminidase inhibitors to be presented by Roche (Tamiflu),Glaxo Wellcome (Relenza), and RW Johnson PRI (RWJ-270201);Agouron's protease inhibitor for rhinovirus infection, andclinical summary of ViroPharma's Pleconaril, a novel therapy forpicornaviral disease, will also be featured. In HIV, the conferences focuses on Trimeris' fusion inhibitor,T-20 and Merck's Integrase inhibitor; also featured will be newwork on reverse transcriptase inhibitors (BioChem Pharma andDuPont), plus contribution from Glaxo Wellcome on resistancetesting as a guide to antiretroviral discovery and development inlight of the recent FDA Advisory Committee meeting. The HBV/HCV section will feature discussion of ScheringPlough's Ribavirin, Roche's Pegainterferon alfa-2a andcontributions from Eli Lilly and Glaxo Wellcome; Emory Universityand Novirio Pharmaceuticals will present new data on nucleosideanalogs and L-nucleosides, both having shown potent activityagainst hepatitis B. To request the agenda and/or register, please contact CamilleCoward of Strategic Research at ccoward@srinstitute.com (includecompany/university and mailing address) or by phone at (USA) 212-967-0095, ext 255; for information on sponsorship & exhibitioncontact Mark Alexay at (USA) 212-967-0095, x251 ormalexay@hotmail.com . ots Original Text Service: StrategicResearch Institute L.P. Internet: http://www.newsaktuell.deContact: Camille Coward, (USA) 212-967-0095 ext. 255, orccoward@srinstitute.com, or Mark Alexay, Sponsorship andExhibition, (USA) 212-967-0095, ext. 251, or malexay@hotmail.com,both of the Strategic Research Institute L.P. Web site:http://www.srinstitute.com
Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.
PROTEXT